Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab
Purpose The presence of wheals or hives has been viewed as a hallmark symptom of urticaria, a highly debilitating disease. This study explores our experience with omalizumab in patients with apparent mast-cell mediated pruritus in the absence of hives.Materials and Methods This is a retrospective ca...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2371545 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850250033704730624 |
|---|---|
| author | Kelsey L. Auyeung Brian S. Kim |
| author_facet | Kelsey L. Auyeung Brian S. Kim |
| author_sort | Kelsey L. Auyeung |
| collection | DOAJ |
| description | Purpose The presence of wheals or hives has been viewed as a hallmark symptom of urticaria, a highly debilitating disease. This study explores our experience with omalizumab in patients with apparent mast-cell mediated pruritus in the absence of hives.Materials and Methods This is a retrospective case series examining all patients with mast cell-mediated pruritus in the absence of hives from April 2022 to May 2024 at a tertiary referral clinic at Icahn School of Medicine at Mount Sinai in New York. Peak pruritus-numerical rating scale (PP-NRS) itch score changes over time were recorded and analyzed.Results Six patients (67% women; mean [SD] age, 47.67 [13.52] years) were included in the analysis. The median [IQR] pruritus PP-NRS itch score before omalizumab injection was 9 [6 – 10] and the final median [IQR] PP-NRS itch score was 2.5 [0 – 5]. The mean [SD] reduction in the PP-NRS itch score was 6 [3.16].Conclusions This study suggests that patients with evidence of mast cell-mediated pruritus can be identified based on clinical features and may benefit from omalizumab therapy. |
| format | Article |
| id | doaj-art-99e069938b024b98aabcfbd34f605c0e |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-99e069938b024b98aabcfbd34f605c0e2025-08-20T01:58:20ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2371545Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumabKelsey L. Auyeung0Brian S. Kim1Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USAKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USAPurpose The presence of wheals or hives has been viewed as a hallmark symptom of urticaria, a highly debilitating disease. This study explores our experience with omalizumab in patients with apparent mast-cell mediated pruritus in the absence of hives.Materials and Methods This is a retrospective case series examining all patients with mast cell-mediated pruritus in the absence of hives from April 2022 to May 2024 at a tertiary referral clinic at Icahn School of Medicine at Mount Sinai in New York. Peak pruritus-numerical rating scale (PP-NRS) itch score changes over time were recorded and analyzed.Results Six patients (67% women; mean [SD] age, 47.67 [13.52] years) were included in the analysis. The median [IQR] pruritus PP-NRS itch score before omalizumab injection was 9 [6 – 10] and the final median [IQR] PP-NRS itch score was 2.5 [0 – 5]. The mean [SD] reduction in the PP-NRS itch score was 6 [3.16].Conclusions This study suggests that patients with evidence of mast cell-mediated pruritus can be identified based on clinical features and may benefit from omalizumab therapy.https://www.tandfonline.com/doi/10.1080/09546634.2024.2371545Itchpruritusmast cellomalizumaburticariahive |
| spellingShingle | Kelsey L. Auyeung Brian S. Kim Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab Journal of Dermatological Treatment Itch pruritus mast cell omalizumab urticaria hive |
| title | Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab |
| title_full | Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab |
| title_fullStr | Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab |
| title_full_unstemmed | Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab |
| title_short | Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab |
| title_sort | treatment of patients with evidence of mast cell mediated itch in the absence of hives with omalizumab |
| topic | Itch pruritus mast cell omalizumab urticaria hive |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2371545 |
| work_keys_str_mv | AT kelseylauyeung treatmentofpatientswithevidenceofmastcellmediateditchintheabsenceofhiveswithomalizumab AT brianskim treatmentofpatientswithevidenceofmastcellmediateditchintheabsenceofhiveswithomalizumab |